We are live on
!
Find out more
RJA
Raymond James & Associates Portfolio holdings
AUM
$164B
1-Year Est. Return
33.91%
This Fund
S&P 500
This Quarter
Est. Return
+2.33%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$152B
AUM Growth
+$4.77B
(+3.2%)
Cap. Flow
+$2.89B
Cap. Flow
% of AUM
1.9%
Top 10 Holdings %
Top 10 Hldgs %
26.78%
Holding
4,133
New
185
Increased
1,882
Reduced
1,701
Closed
184
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
+$255M |
| 2 |
Apple
AAPL
|
+$184M |
| 3 |
NextEra Energy
NEE
|
+$153M |
| 4 |
Walmart Inc
WMT
|
+$141M |
| 5 |
Public Service Enterprise Group
PEG
|
+$119M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$157M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$110M |
| 3 |
NVIDIA
NVDA
|
+$90.1M |
| 4 |
Vistra
VST
|
+$72.2M |
| 5 |
Union Pacific
UNP
|
+$58.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.11% |
| 2 | Financials | 8.61% |
| 3 | Healthcare | 7.69% |
| 4 | Industrials | 6.49% |
| 5 | Consumer Discretionary | 5.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
Opendoor
OPEN
$3.39B
| $37K | ﹤0.01% |
20,786
-853
| -4% | -$1.84K |
|
3802
Xilio Therapeutics
XLO
$60.4M
| $36.8K | ﹤0.01% |
+2,773
| New | +$43.4K |
|
3803
Cytosorbents Corp
CTSO
$23.9M
| $35.1K | ﹤0.01% |
50,000
| – | – |
|
3804
SCYNEXIS
SCYX
$46.9M
| $34.8K | ﹤0.01% |
2,174
| – | – |
|
3805
Innoviz Technologies
INVZ
$115M
| $34.7K | ﹤0.01% |
37,385
+3,600
| +11% | +$4.04K |
|
3806
Denison Mines
DNN
$2.98B
| $34.2K | ﹤0.01% |
17,180
-5,350
| -24% | -$11.4K |
|
3807
EVgo
EVGO
$500M
| $33.9K | ﹤0.01% |
13,842
-5,239
| -27% | -$10.7K |
|
3808
CarParts.com
PRTS
$50.9M
| $33.8K | ﹤0.01% |
3,381
| – | – |
|
3809
Eton Pharmaceutcials
ETON
$1.14B
| $33.7K | ﹤0.01% |
10,250
| – | – |
|
|
SPWR
3810
DELISTED
SunPower Corporation Common Stock
SPWR
| $33.1K | ﹤0.01% |
11,181
-8,977
| -45% | -$24.5K |
|
|
LAC
3811
Lithium Americas
LAC
$1.17B
| $32.7K | ﹤0.01% |
12,218
-9,899
| -45% | -$43.7K |
|
3812
Standard BioTools
LAB
$311M
| $32.2K | ﹤0.01% |
18,194
| – | – |
|
3813
Aveanna Healthcare
AVAH
$2.04B
| $30.5K | ﹤0.01% |
+11,052
| New | +$27.6K |
|
3814
Fossil Group
FOSL
$309M
| $30.3K | ﹤0.01% |
21,053
| – | – |
|
|
UROY
3815
Uranium Royalty Corp
UROY
$1.56B
| $30.3K | ﹤0.01% |
+13,450
| New | +$33.4K |
|
3816
PUT
Energy Transfer Partners
ET
$71.2B
| $30K | ﹤0.01% |
2,500
| – | – |
|
|
TELL
3817
DELISTED
Tellurian Inc.
TELL
| $29.9K | ﹤0.01% |
43,221
+9,000
| +26% | +$4.98K |
|
3818
Sol-Gel Technologies
SLGL
$274M
| $29.9K | ﹤0.01% |
3,363
+265
| +9% | +$2.21K |
|
|
NEXI
3819
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $29.8K | ﹤0.01% |
10,804
| – | – |
|
3820
Trevi Therapeutics
TRVI
$2.55B
| $29.8K | ﹤0.01% |
10,000
| – | – |
|
|
ME
3821
DELISTED
23andMe Holding Co
ME
| $29.6K | ﹤0.01% |
3,781
-500
| -12% | -$4.79K |
|
|
DRRX
3822
DELISTED
DURECT Corp
DRRX
| $28.5K | ﹤0.01% |
22,130
+3,630
| +20% | +$4.27K |
|
|
DNMR
3823
DELISTED
Danimer Scientific, Inc.
DNMR
| $27.8K | ﹤0.01% |
1,151
-340
| -23% | -$10.6K |
|
3824
Bullfrog AI
BFRG
$11.3M
| $25.9K | ﹤0.01% |
+15,000
| New | +$41.9K |
|
3825
Fathom Holdings
FTHM
$24.8M
| $25.8K | ﹤0.01% |
+15,000
| New | +$25K |
|
Similar funds
RJFSA
PI
ECU
EAM
AA
SA
WPL
ECU
Raymond James & Associates's Q2 2024 Portfolio in Review
As of Q2 2024, Raymond James & Associates held 4,133 positions worth $152B, up 3.2% from $148B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Raymond James & Associates's Q2 2024 filing shows 185 new, 1,882 increased, 1,701 reduced and 184 closed positions. Its largest new stake was Solventum: 321,226 shares worth $17M. The largest sale was State Street Health Care Select Sector SPDR ETF, an estimated $157M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.
- Raymond James & Associates's largest Q2 2024 buy was Solventum: 321,226 shares worth $17M.
- Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q2 2024, an estimated $255M increase.
- Raymond James & Associates's biggest Q2 2024 reduction was State Street Health Care Select Sector SPDR ETF, cutting an estimated $157M.
- Raymond James & Associates fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $110M.
- Raymond James & Associates's ten largest holdings make up 27% of its $152B portfolio in Q2 2024.
- Raymond James & Associates opened 185 new positions and closed 184 in Q2 2024.
- Raymond James & Associates's portfolio value rose 3.2% quarter-over-quarter to $152B.
Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.